Page 186 - 2019_02-Haematologica-web

E. Maffini et al.
parison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110-1120.
9. Giaccone L, Storer B, Patriarca F, et al. Long- term follow-up of a comparison of non- myeloablative allografting with autograft- ing for newly diagnosed myeloma. Blood. 2011;117(24):6721-6727.
10. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose- reduced allograft (IFM99-03 trial) with tan- dem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multi- ple myeloma. Blood. 2006;107(9):3474- 3480.
11. Moreau P, Garban F, Attal M, et al. Long- term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloabla- tive allotransplantation with autologous transplantation in high-risk de novo multi- ple myeloma. Blood. 2008;112(9):3914- 3915.
12. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diag- nosed multiple myeloma. Blood. 2008; 112(9):3591-3593.
13. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell trans- plantation followed by allogeneic or autol- ogous haemopoietic stem-cell transplanta- tion in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12(13):1195-1203.
14. Lokhorst HM, van der Holt B, Cornelissen JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012;119(26):6219- 6225.
15. Gahrton G, Iacobelli S, Bjorkstrand B, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long- term results of the EBMT-NMAM2000 study. Blood. 2013;121(25):5055-5063.
16. Rotta M, Storer BE, Sahebi F, et al. Long- term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009;113(14):3383- 3391.
17. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412- 3420.
18. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
19. Patel K, Orlowski RZ, Shah N, et al. Role of serum lactate dehydrogenase (LDH) as a prognostic marker for autologous hematopoietic stem cell transplantation for multiple myeloma (abstract). Blood. 2012;120(21):3115-3115.
20. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106(8):2837-2840.
21. Neben K, Jauch A, Bertsch U, et al. Combining information regarding chromo- somal aberrations t(4;14) and del(17p13) with the International Staging System clas- sification allows stratification of myeloma patients undergoing autologous stem cell
transplantation. Haematologica. 2010;
95(7):1150-1157.
22. Teoh PJ, Chung TH, Sebastian S, et al. p53
haploinsufficiency and functional abnor- malities in multiple myeloma. Leukemia. 2014;28(10):2066-2074.
23. Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012; 26(2):349-355.
24. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluores- cence in situ hybridization: incidence increases from MGUS to relapsed myelo- ma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108(5):1724- 1732.
25. Van Wier S, Braggio E, Baker A, et al. Hypodiploid multiple myeloma is charac- terized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica. 2013; 98(10):1586-1592.
26. Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multi- ple myeloma. Blood. 2005;106(7):2276- 2279.
27. Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over- represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761-1767.
28. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high- risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.
29. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92(10): 3515-3520.
30. Sandmaier BM, Maloney DG, Storer BE, et al. Sirolimus combined with mycopheno- late mofetil (MMF) and cyclosporine (CSP) significantly improves prevention of acute graft-versus-host-disease (GVHD) after unrelated hematopoietic cell transplanta- tion (HCT): Results from a phase III ran- domized multi-center trial. Blood. 2016; 128(22):#506 (abstract); http://www.blood- journal.org/content/128/522/506.
31. Martin PJ. Documentation of engraftment and characterization of chimerism after hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation, 5th Edition. Chichester, UK: John Wiley & Sons, Ltd, 2016:272-280.
32. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and mini- mal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328- e346.
33. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
34. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study
of 20 Seattle patients. Am J Med. 1980;69:
204-217.
35. Attal M, Harousseau JL, Stoppa AM, et al.
A prospective, randomized trial of autolo- gous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91-97.
36. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23(36):9227-9233.
37. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoi- etic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-1883.
38. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplan- tation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.
39. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and mainte- nance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895-905.
40. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexam- ethasone with transplantation for myelo- ma. N Engl J Med. 2017;376(14):1311-1320.
41. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem- cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434-2441.
42. Sonneveld P, van der Holt B, Segeren CM, et al. Intermediate-dose melphalan com- pared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica. 2007;92(7): 928-935.
43. Mai EK, Benner A, Bertsch U, et al. Single versus tandem high-dose melphalan fol- lowed by autologous blood stem cell trans- plantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173(5):731-741.
44. Perez-Simon JA, Sureda A, Fernandez- Aviles F, et al. Reduced-intensity condition- ing allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia. 2006;20(3):542-545.
45. Byrne JL, Fairbairn J, Davy B, Carter IG, Bessell EM, Russell NH. Allogeneic trans- plantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Bone Marrow Transplant. 2003;31(3):157-161.
46. Vincent L, Ceballos P, Plassot C, et al. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Blood Cancer J. 2015;5:e341.
47. Giaccone L, Brunello L, Festuccia M, et al. Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. Bone Marrow Transplant. 2015;50(4):511- 516.
48. Ladetto M, Ferrero S, Drandi D, et al. Prospective molecular monitoring of mini- mal residual disease after non-myeloabla- tive allografting in newly diagnosed multi- ple myeloma. Leukemia. 2016;30(5):1211- 1214.
49. Ringdén O, Shrestha S, da Silva GT, et al. Effect of acute and chronic GVHD on
390
haematologica | 2019; 104(2)